TRUXIMA Drug Profile

Summary for Tradename: TRUXIMA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TRUXIMA

Recent Clinical Trials for TRUXIMA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)	Phase 4
Universitaire Ziekenhuizen KU Leuven	Phase 4
Fate Therapeutics	Phase 1

See all TRUXIMA clinical trials

Pharmacology for TRUXIMA

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TRUXIMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TRUXIMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TRUXIMA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for TRUXIMA

Last updated: April 8, 2026

What Is TRUXIMA?

TRUXIMA (rituximab-abbs) is a biosimilar to Rituximab, originally marketed as Rituxan. Approved in 2018 by the FDA, TRUXIMA is indicated for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. It is developed by Amgen.

Market Position and Competitive Landscape

Key Market Players

• Amgen: Manufacturer of TRUXIMA, the first biosimilar of rituximab approved in the United States.
• Roche/Genentech: Producer of the originator Rituxan, marketed in the U.S. and globally.
• Other Biosimilars: Multiple biosimilars entering markets, including Sandoz's Rixathon, Celltrion's Truxima, and Teva's Ruxience.

Market Share and Adoption

• In the U.S., TRUXIMA captured approximately 25% of rituximab prescribing volume within a year of launch (GoodRx, 2020).
• Globally, biosimilar uptake varies, with higher adoption in Europe following price reductions and regulatory support.

Drivers

• Cost competitiveness: Biosimilars typically reduce costs by 15-30% compared to originator biologics.
• Regulatory approval pathways and policies promoting biosimilar use.
• Physician and payer acceptance, driven by clinical data showing equivalence.

Barriers

• Prescriber inertia due to familiarity with Rituxan.
• Payer negotiations and formulary preferences favoring originator brands initially.
• Limited clinical switching data early on, slowing uptake.

Financial Trajectory Analysis

Revenue Generation

• Estimated global rituximab sales in 2022 exceeded USD 7 billion (EvaluatePharma, 2023).
• Biosimilar share was approximately 20% in 2022, with a trend toward increasing adoption.
• In the U.S., TRUXIMA's revenue approximated USD 600 million in 2022, representing a significant share of Amgen's biosimilar portfolio.

Revenue Projection

Year	Estimated Revenue (USD millions)	Assumptions
2023	700–800	Continued uptake, price erosion stabilization
2024	850–950	Market expansion, new indications
2025	950–1,100	Payer policies favor biosimilars
2026	1,200+	Greater prescribing acceptance

Cost Factors

• Manufacturing costs for biosimilars are estimated at 20–30% lower than originator biologics.
• Launch costs include regulatory submission, clinical data, and market access efforts, averaging USD 150–200 million per biosimilar.

Profitability Outlook

• Gross margins are dependent on price discounts and market penetration.
• Amgen's biosimilars segment reports margins of around 40%, with potential for growth as uptake increases.

Regulatory and Policy Impact

• The FDA and EMA have streamlined pathways for biosimilar approval, reducing time-to-market.
• U.S. policies, such as automatic substitution laws in some states, could accelerate biosimilar adoption.
• European Union's biosimilar guidelines have supported increased savings and drug competition.

Market Challenges and Opportunities

Challenges

• Prescriber and patient resistance due to brand loyalty and misconceptions about biosimilar efficacy.
• Patent litigations and exclusivity periods delaying biosimilar entry in some regions.
• Price erosion pressures from multiple biosimilars entering the market.

Opportunities

• Expansion into additional indications, such as autoimmune diseases.
• Strategic collaborations for broader distribution.
• Enhanced education campaigns to increase acceptance.

Key Takeaways

• TRUXIMA has established a foothold in the rituximab biosimilar market, with revenues projected to gradually increase over the next three years.
• Adoption remains influenced by pricing, policy, and clinician preferences, with ongoing improvement expected.
• The biosimilar segment is expected to grow rapidly, driven by cost savings and expanding indications.
• A combination of market competition and regulatory policies poses both challenges and expansion opportunities.

FAQs

1. What is the main driver for biosimilar success like TRUXIMA?
Cost savings and regulatory acceptance facilitate market penetration, supported by policies that encourage biosimilar use.

2. How does TRUXIMA compare price-wise to Rituxan?
Biosimilars generally reduce costs by 15-30%. Exact pricing varies by region and payer negotiations.

3. Will TRUXIMA expand into new indications?
Yes, ongoing clinical trials seek approval for additional autoimmune and hematologic conditions.

4. What are the primary obstacles to biosimilar adoption?
Prescriber resistance, limited switching data initially, and patent litigations.

5. What is the outlook for TRUXIMA’s market share?
Expected to grow steadily as biosimilar acceptance improves and cost benefits are realized.

References

[1] EvaluatePharma. (2023). World Combined Brand-Name and Biosimilar Biotechnology Market Data.
[2] GoodRx. (2020). Biosimilar Rituximab: Market Share and Pricing Data.
[3] U.S. Food and Drug Administration. (2018). FDA Approvals for Biosimilars.